Moreover, miR-22 treatment effectively silenced hypoxia-inducible factor 1 (HIF1α) and enhanced RA signaling in both hepatocytes and T cells, which improved metabolism and anti-tumor immunity. Here, HIF1A is linked to neoplasm.